Anrikefon

Synonyms: HSK21542
Anrikefon 是一种外周限制性 κ 阿片受体 (KOR) 激动剂,对人源 KOR 的 IC50 为 0.54 nM、EC50 为 2.41 pM、Ka 为 0.068 nM,并对 μ 和 δ 阿片受体具有高选择性,可通过抑制炎症性、术后和神经性疼痛相关行为产生镇痛作用,也可通过减少瘙痒相关行为发挥止痒作用,因此可用于疼痛、瘙痒及慢性肾脏病相关瘙痒的研究。
产品编号: MS-R05127 CAS No.: 2269511-95-5 分子式: C39H57N7O5 分子量: 703.91
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Anrikefon 是一种外周限制性 κ 阿片受体 (KOR) 激动剂,对人源 KOR 的 IC50 为 0.54 nM、EC50 为 2.41 pM、Ka 为 0.068 nM,并对 μ 和 δ 阿片受体具有高选择性,可通过抑制炎症性、术后和神经性疼痛相关行为产生镇痛作用,也可通过减少瘙痒相关行为发挥止痒作用,因此可用于疼痛、瘙痒及慢性肾脏病相关瘙痒的研究。

生物实验数据

生物活性 Anrikefon is a peripherally restricted κ opioid receptor (KOR) agonist with an IC50 of 0.54 nM, an EC50 of 2.41 pM, and a Ka of 0.068 nM for human KOR, and exhibits high selectivity over μ and δ opioid receptors; it produces analgesic effects by inhibiting inflammatory, postoperative, and neuropathic pain-related behaviors and exerts antipruritic effects by reducing itch-related behaviors, and can therefore be used for research on pain, pruritus, and chronic kidney disease-associated pruritus.
IC50 & Target

κ Opioid Receptor/KOR

 

体外研究
(In Vitro)

Anrikefon (HSK21542) (0.01-10 nM, 0.123-1.23 nM; 60 min, 120 min) 可在分离的 HEK-293 细胞膜中强效结合人源 KOR,其 IC50 为 0.54 nM,Kd 为 0.068 nM,解离半衰期长达 90.6 min。
Anrikefon (HSK21542) (0.001-10 nM; 30 min) 可强效抑制表达人 KOR 的 HEK-293 细胞中 forskolin 诱导的 cAMP 积累,其 EC50 为 2.41 pM。
Anrikefon (HSK21542) (10 μM) 具有高脱靶选择性,仅在 10 μM 的高浓度下与大麻素 CB1 受体有微弱结合,且对其他 85 种受试靶点无活性。

体内研究
(In Vivo)

Anrikefon (HSK21542) (0.03-30 mg/kg; i.v.; single dose) 在 Mus musculus 醋酸扭体模型中可产生强效、剂量依赖性、由 KOR 介导的镇痛作用,给药后 15 分钟的最低有效剂量为 0.03 mg/kg,且药效至少可持续至给药后 24 小时。
Anrikefon (HSK21542) (0.1-10 mg/kg; i.v.; single dose) 在大鼠后爪切口术后疼痛模型中可产生剂量依赖性的抗异常痛觉效应,当给药剂量为 3 mg/kg 和 10 mg/kg 时,其药效在给药后至少 24 小时仍可检测到。
Anrikefon (HSK21542) (0.1-3 mg/kg; i.v.; single dose) 在大鼠 CCI 神经病理性疼痛模型中可产生具有剂量依赖性的持续抗异常痛觉作用,其最低有效剂量为 0.3 mg/kg,且在 1 mg/kg 和 3 mg/kg 剂量下,给药后药效至少持续 24 小时。
Anrikefon (HSK21542) (0.01-3 mg/kg; i.v.; single dose) 在化合物 48/80 诱导的小鼠搔抓模型中可产生强效的、剂量依赖性止痒作用,其最低有效剂量为 0.03 mg/kg,在 1 mg/kg 剂量下可实现近乎完全抑制。
Anrikefon (HSK21542) (3.75-7.5 mg/kg; i.v.; single dose) 在小鼠热板试验中表现出较弱的中枢镇痛作用,其最小有效剂量为 7.5 mg/kg,显著高于发挥外周镇痛和止痒活性所需的剂量。
Anrikefon (HSK21542) (0.4-2 mg/kg; i.v.; single dose) 仅在较高剂量 (2 mg/kg) 时对 Rattus norvegicus(rats) 产生轻度镇静作用,在最高达 0.4 mg/kg 的剂量下无显著作用。
Anrikefon (HSK21542) (0.4-2 mg/kg; i.v.; single dose) 在剂量高达 2 mg/kg 时不会显著改变小鼠的呼吸频率,表明其具有良好的呼吸安全性特征。
Anrikefon (1-10 mg/kg/天;静脉注射;每 6 小时给药 1 次,每日 2 次) 在剂量高达 10 mg/kg/天时对雄性大鼠的生育力或早期胚胎发育无具有毒理学意义的影响,但在所有受试剂量下会延长雌性大鼠的动情周期时长并提高紊乱率,导致雌性生育力毒性的 NOAEL 低于 1 mg/kg/天。
Anrikefon (0.2-4 mg/kg/天;静脉注射;每 6 小时给药 1 次,每日 2 次) 对 rats 的胚胎-胎仔发育的 NOAEL 为 1 mg/kg/天,仅在 4 mg/kg/天剂量下观察到胸椎椎体骨化不完全的发生率略有升高。
Anrikefon (0.3-2 μg/kg/日;静脉注射;每日给药) 对家兔胚胎-胎仔发育的 NOAEL 为 2 μg/kg/日,在所有受试剂量下均未观察到具有毒理学意义的不良反应。
Anrikefon (0.2-4 mg/kg/day; i.v.; twice a day at 6-hour intervals) 对大鼠的出生前后发育的 NOAEL 为 4 mg/kg/天,在所有测试剂量下均未观察到对母鼠或子代相关指标具有毒理学意义的不良反应。

Animal Model: ICR (18-22 g, 8-10 weeks old, half male and half female; acetic acid-induced writhing modeling)
Dosage: 0.03-30 mg/kg
Administration: i.v.; single dose
Result: Induced a 27.46% inhibitory rate on writhing behaviors at 0.03 mg/kg (15 minutes post-dosing). Produced dose-dependent increases in inhibitory efficacy at 0.1 mg/kg and higher doses (15 minutes post-dosing), with effects comparable to CR845 at equivalent doses. Reached a median effective dose (ED50) of 0.09 mg/kg (95% CI: 0.06-0.12 mg/kg) at 15 minutes post-dosing. Induced a 32.75% inhibitory rate at 0.3 mg/kg (24 hours post-dosing). Induced a 49.67% inhibitory rate at 1 mg/kg (24 hours post-dosing). Induced a 55.60% inhibitory rate at 3 mg/kg (24 hours post-dosing). Induced a 68.12% inhibitory rate at 10 mg/kg (24 hours post-dosing). Induced a 75.16% inhibitory rate at 30 mg/kg (24 hours post-dosing). Reached an ED50 of 1.48 mg/kg (95% CI: 0.62-2.45 mg/kg) at 24 hours post-dosing. Showed antinociceptive effects at 0.3 mg/kg and 1 mg/kg that were completely reversed by pre-treatment with nor-binaltorphimine.
Animal Model: Sprague Dawley (SD) (160-180 g, 8-10 weeks old, male; hindpaw incision modeling)
Dosage: 0.1-10 mg/kg
Administration: i.v.; single dose
Result: Induced a 10.5-fold increase in 50% paw withdrawal threshold (PWT; 7.51 g vs. 0.72 g in vehicle controls) at 1 mg/kg (15 minutes post-dosing). Produced maximum antiallodynic activity at 10 mg/kg (15 minutes post-dosing). Had a minimum effective dose (MED) of 1 mg/kg. Maintained statistically significant increases in mechanical pain thresholds at 3 mg/kg and 10 mg/kg compared to vehicle controls (24 hours post-dosing).
Animal Model: Sprague Dawley (SD) (160-180 g, 8-10 weeks old, male; chronic constriction injury [CCI] modeling)
Dosage: 0.1-3 mg/kg
Administration: i.v.; single dose
Result: Induced a 5.15-fold increase in 50% PWT (6.62 g vs. 1.29 g in vehicle controls) at 0.3 mg/kg (15 minutes post-dosing). Produced peak 50% PWT values at 2 hours post-dosing at 1 mg/kg and 3 mg/kg, which gradually declined but remained significantly elevated compared to vehicle controls at 24 hours post-dosing. Showed a significantly increased AUC for 50% PWT over time at all doses tested, with the MED defined as 0.3 mg/kg.
Animal Model: ICR (18-22 g, 8-10 weeks old, male; compound 48/80-induced scratching modeling)
Dosage: 0.01-3 mg/kg
Administration: i.v.; single dose
Result: Produced dose-dependent inhibition of scratching behaviors. Induced a 34.89% inhibitory rate at 0.03 mg/kg. Induced a 53.02% inhibitory rate at 0.1 mg/kg. Induced a 73.75% inhibitory rate at 0.3 mg/kg. Induced a peak 99.78% inhibitory rate at 1 mg/kg. Had a MED of 0.03 mg/kg, and an ED50 of 0.09 mg/kg (95% CI: 0.04-0.16 mg/kg), with efficacy comparable to CR845 at equivalent doses.
Animal Model: C57BL/6J (18-22 g, 8-10 weeks old, female)
Dosage: 3.75-7.5 mg/kg
Administration: i.v.; single dose
Result: Did not produce a significant increase in % MPE at 3.75 mg/kg. Induced a 29.60% MPE at 7.5 mg/kg, which was statistically significant compared to vehicle controls. Reached an ED50 of 10.49 mg/kg (95% CI: 7.58-15.37 mg/kg).
Animal Model: Sprague Dawley (SD) (160-180 g, 8-10 weeks old, half male and half female)
Dosage: 0.4 mg/kg; 2 mg/kg
Administration: i.v.; single dose
Result: Did not produce a significant reduction in total distance traveled compared to vehicle controls at 0.4 mg/kg. Induced a statistically significant reduction in locomotor activity at 2 mg/kg.
Animal Model: ICR (18-22 g, 8-10 weeks old, half male and half female)
Dosage: 0.4 mg/kg; 2 mg/kg
Administration: i.v.; single dose
Result: Did not produce a statistically significant change in respiratory rate compared to vehicle controls at 0.4 mg/kg or 2 mg/kg at any time point tested.
Animal Model: Sprague-Dawley rats (8-11 weeks, both sexes, fertility and early embryonic development model)
Dosage: 1 mg/kg/day; 3 mg/kg/day; 10 mg/kg/day
Administration: i.v.; twice a day at 6-hour intervals; males: 4 weeks prior to mating through mating period until day before necropsy; females: 2 weeks prior to mating through mating period until gestation day 15
Result: Increased male rat sperm count to 440.6 ×10^6 (1 mg/kg/day) and 436.7 ×10^6 (10 mg/kg/day).\nIncreased male rat sperm density to 704.1 ×10^6/g (1 mg/kg/day) and 722.4 ×10^6/g (10 mg/kg/day).\nLeft male rat sperm motility and malformation rate unchanged across all doses.\nIncreased female rat estrous cycle length to 4.4 days (1 mg/kg/day), 4.5 days (3 mg/kg/day), and 4.6 days (10 mg/kg/day).\nIncreased female rat estrous cycle disorder rate to 65.4% (1 mg/kg/day), 61.5% (3 mg/kg/day), and 57.7% (10 mg/kg/day).\nIncreased female rat precoital interval to 3.2 days (10 mg/kg/day).\nDecreased female rat gravid uterus weight to 15.805 g (1 mg/kg/day).\nLeft female rat copulation index, conception index, fertility index, corpora lutea count, implantation sites, resorptions, viable embryos, and pre/post-implantation loss unchanged across all doses.
Animal Model: Sprague-Dawley rats (pregnant females, embryo-fetal developmental model)
Dosage: 0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day
Administration: i.v.; twice a day at 6-hour intervals; gestation day 6 through gestation day 17
Result: Caused transient, mild decreases in maternal rat body weight (3.56-6.33%) from GD 8 to GD 10 in the 1 and 4 mg/kg/day groups.\nDecreased maternal rat food consumption from GD 6 to GD 7 across all doses.\nLeft maternal rat corpora lutea count, implantation sites, resorptions, viable fetuses, post-implantation loss, and organ weights unchanged across all doses.\nLeft fetal rat weight and crown-rump length unchanged across all doses.\nIncreased the incidence of fetuses with incomplete ossification of thoracic vertebral centrum by 3.5% in the 4 mg/kg/day group.\nDecreased incomplete ossification of pubis, hyoid bone, and 5th/6th sternebra in the 1 mg/kg/day group, and decreased incomplete ossification of hyoid bone in the 4 mg/kg/day group (deemed not toxicologically significant).\nIncreased 14th rudimentary ribs in the 4 mg/kg/day group (deemed incidental).
Animal Model: New Zealand white rabbits (5-6 months, pregnant females, embryo-fetal developmental model)
Dosage: 0.3 μg/kg/day; 1 μg/kg/day; 2 μg/kg/day
Administration: i.v.; daily; gestation day 7 through gestation day 19
Result: Left maternal rabbit body weight, food consumption, corpora lutea count, implantation sites, resorptions, viable fetuses, post-implantation loss, and organ weights unchanged across all doses.\nLeft fetal rabbit weight and crown-rump length unchanged across all doses.\nDecreased male fetus ratio to 32% in the 2 μg/kg/day group (deemed not toxicologically significant).\nLeft fetal rabbit external, visceral, and skeletal malformations or variations unchanged across all doses.
Animal Model: Sprague-Dawley rats (pregnant females and their offspring, pre- and post-natal development model)
Dosage: 0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day
Administration: i.v.; twice a day at 6-hour intervals; gestation day 6 through postnatal day 21
Result: Caused transient, mild decreases in maternal rat body weight (4.04-6.56%) from GD 8 to GD 17 in the 1 and 4 mg/kg/day groups (deemed not treatment-related).\nDecreased maternal rat food consumption from GD 6 to GD 7 in the 1 and 4 mg/kg/day groups, and increased food consumption from GD 10 to GD 11 in the 1 mg/kg/day group (deemed not treatment-related).\nIncreased maternal rat resorptions in the 1 mg/kg/day group (deemed not toxicologically significant).\nLeft maternal rat gestation length, corpora lutea count, implantation sites, viable fetuses, post-implantation loss, litter size, and live birth/viability/lactation indices unchanged across all doses.\nLeft offspring pre-weaning and post-weaning body weights largely unchanged, with minor, non-toxicologically significant increases in female offspring body weight on PND 63 and 70 at 1 and 4 mg/kg/day.\nLeft offspring reflex development, locomotor activity, learning behavior, sexual maturation, and reproductive capacity unchanged across all doses.\nIncreased offspring placenta weight in the 4 mg/kg/day group (deemed not toxicologically significant).

化学信息

分子量 703.91
分子式 C39H57N7O5
CAS No. 2269511-95-5
别名 HSK21542

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础